Skip to main content

Table 3 Univariate analyses for recurrence-free and overall survival in patients with clinical stage I NSCLC

From: Prognostic significance of preoperative plasma D-dimer level in patients with surgically resected clinical stage I non-small cell lung cancer: a retrospective cohort study

 

RFS

OS

Variables

HR (95% CI)

P value

HR (95% CI)

P value

Age at operation, y

    

 <70

1

 

1

 

 ≥70

1.12 (0.56–2.14)

0.762

2.31 (1.12–5.13)

0.031

Gender

 Female

1

 

1

 

 Male

1.13 (0.54–2.28)

0.668

1.02 (0.78–1.52)

0.869

Smoking habit

 Never smoker

1

 

1

 

 Ever smoker

1.22 (0.88–1.72)

0.281

1.21 (0.86–1.82)

0.225

Serum CEA, ng/ml

 ≤5

1

 

1

 

 >5

2.11 (1.03–4.12)

0.049

2.42 (1.31–5.46)

0.019

Extent of pulmonary resection

 Segmentectomy

1

 

1

 

 Lobectomy or more

0.75 (0.56–1.21)

0.221

0.81 (0.55–1.26)

0.231

Tumor location

 Central

1

 

1

 

 Non-central

0.94 (0.44–1.86)

0.852

0.58 (0.79–4.22)

0.586

SUVmax of primary tumor

 ≤2.3

1

 

1

 

 >2.3

5.89 (3.45–14.2)

<0.001

3.89 (1.64–9.01)

0.001

D-dimer, μg/ml

 ≤1.0

1

 

1

 

 >1.0

2.62 (1.41–5.61)

0.019

2.67 (1.23–5.12)

0.021

Tumor size, cm

 ≤3

1

 

1

 

 >3

1.32 (0.64–2.72)

0.483

1.16 (0.54–2.76)

0.688

Histological type

    

 AD

1

 

1

 

 Others

1.33 (0.64–2.76)

0.486

1.35 (0.64–2.81)

0.479

Grade

    

 1

1

 

1

 

 2 / 3 / 4

1.33 (0.61–2.79)

0.438

1.41 (0.68–2.82)

0.439

Pleural invasion

 Absent

1

 

1

 

 Present

2.42 (1.06–5.52)

0.038

1.95 (0.76–5.01)

0.181

Pathological stage

 Stage I

1

 

1

 

 Stage II/III

5.61 (3.22–9.12)

<0.001

3.91 (1.65–8.98)

0.001

  1. NSCLC non-small cell lung cancer, CEA carcinoembryonic antigen, AD adenocarcinoma, SUVmax maximum standardized uptake value, RFS recurrence-free survival, OS overall survival, HR hazard ratio, CI confidence interval